This advanced technology targets fat cells at a single or multiple depths of the fat layer simultaneously in a single pulse of energy. This allows for treatment of a larger volume of fat and provides a more customized body sculpting solution for a greater patient population.

“This innovative technology is unique to the UltraShape V3 platform as it is not available in any other non-invasive fat reduction and body sculpting device in the world. Integrating the VDF multi-focus ultrasound technology allows for a more effective treatment to a wider audience "commented Assaf Eyal, President and CEO of UltraShape Ltd.

 The device is expected to be immediately released via distributors, to the markets in Europe and South America.

About UltraShape
UltraShape redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for body contouring and fat reduction. The company is dedicated to providing clinically proven safe and effective solutions that enhance the lives of patients worldwide. The UltraShape proprietary technology is based on focused ultrasound that targets and selectively disrupts fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices worldwide, demonstrating safety and efficacy.

The Contour I system has not been approved by the FDA for sale in the United States.
Contour I and RFVac are trademarks and UltraShape is a registered trademark of UltraShape Ltd.
UltraShape Ltd. is a unit of UltraShape Medical Ltd. (Tel Aviv: ULSP)

For more information please visit http://www.ultrashape.com

Contact:

Tal Fishman
Kwan Communications
+972 50 460 0140